^
    Back
    Association details:
    Biomarker:MLL rearrangement
    Cancer:Acute Myelogenous Leukemia
    Drug:Ibrance (palbociclib) (CDK4 inhibitor, CDK6 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Phase Ib/IIa study of palbociclib in MLL-rearranged acute leukemias Eine Phase Ib/IIa Studie zur Therapie mit Palbociclib bei Patienten mit akuter Leukämie und einer Veränderung im MLL-Gen

    Excerpt:
    ......
    Trial ID:
    2014-003647-34
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study of Palbociclib in MLL-rearranged Acute Leukemias

    Excerpt:
    ......
    Trial ID:
    NCT02310243
    Less C2 evidence
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2018
    Title:

    Recurrent Genomic Aberrations of D-Type Cyclins Are Therapeutic Targets of CDK4/6 Inhibitors in t(8;21) and MLL-Rearranged Acute Myeloid Leukemia

    Published date:
    11/01/2018
    Excerpt:
    …we also examined the effects of CDK4/6 inhibitors (abemaciclib and palbociclib) on two t(8;21) AML cell lines (Kasumi-1 and SKNO-1) and five MLL-rearrangement AML cell lines (ML-2, MV4-11, MOLM-13, THP-1, and NOMO-1) were analyzed. All cell lines described above exhibited impaired proliferation after treatment with CDK4/6 inhibitors.
    DOI:
    10.1182/blood-2018-99-111073